LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Rhea-AI Summary

LIXTE Biotechnology Holdings (Nasdaq: LIXT) has received a Notice of Allowance from the USPTO for a patent application covering the combination of its LB-100 compound with various cancer immunotherapies. This patent strengthens LIXTE's intellectual property portfolio and highlights its commitment to innovative cancer research. The company is currently conducting clinical trials at the Netherlands Cancer Institute and MD Anderson Cancer Center, testing LB-100 in combination with immunotherapies for metastatic colon cancer and ovarian clear cell carcinoma. LIXTE recently signed an exclusive patent license agreement with NINDS and NCI, opening up opportunities for developing novel combination therapies in cancer treatment.

Positive

• Received Notice of Allowance for a new patent covering LB-100 combination with cancer immunotherapies
• Ongoing clinical trials at prestigious institutions testing LB-100 with immunotherapies
• Exclusive patent license agreement with NINDS and NCI for potential novel combination therapies

Negative

• None.

Insights

Biotechnology Patent Analyst

This patent issuance for LIXTE's LB-100 in combination with cancer immunotherapies is a significant development for the company's intellectual property portfolio. It strengthens LIXTE's position in the competitive oncology market by protecting their innovative approach of combining PP2A inhibition with immunotherapies.

The patent's scope, covering combinations with "various innovative cancer immunotherapies," suggests broad protection and potential for multiple applications. This could lead to increased partnering opportunities and licensing revenue streams for LIXTE.

However, investors should note that while patents are valuable assets, they don't guarantee commercial success. The true value will depend on the clinical trial outcomes and eventual market adoption of LB-100 combinations.

Oncology Research Specialist

LIXTE's approach of combining LB-100, a PP2A inhibitor, with immunotherapies is scientifically intriguing. PP2A inhibition could potentially enhance the efficacy of immune checkpoint inhibitors by modulating immune cell function and tumor microenvironment.

The ongoing trials at NKI and MD Anderson are particularly noteworthy. The MSI Low metastatic colon cancer trial addresses an unmet need, as these tumors typically respond poorly to immunotherapy. Similarly, the ovarian clear cell carcinoma trial targets a notoriously challenging subtype.

If successful, these combinations could expand the patient population benefiting from immunotherapies, potentially transforming treatment paradigms for these difficult-to-treat cancers.

Pharmaceutical Industry Analyst

LIXTE's collaboration with major players like Roche and GSK through investigator-initiated trials is a smart strategy. It allows LIXTE to leverage the resources and expertise of larger companies while retaining control of their compound.

The involvement in Roche's imCORE Network is particularly valuable, as it provides access to a collaborative ecosystem of leading academic institutions and industry partners. This could accelerate LB-100's development and increase its visibility within the oncology community.

The recent NIH license agreement further enhances LIXTE's potential by providing access to additional intellectual property. However, investors should monitor the company's cash position and burn rate, as clinical development is expensive and LIXTE may need additional funding to fully capitalize on these opportunities.

Patent Covers Combining LIXTE’s LB-100
with Various Innovative Cancer Immunotherapies

PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent application number 16/467,721, titled, "Oxabicycloheptanes for Modulation of Immune Response,” for combining the Company’s LB-100 compound with various innovative cancer immunotherapies.

“The patent award further bolsters LIXTE’s existing intellectual property portfolio and underscores the Company’s commitment to pioneering research and delivering innovative solutions to patients battling cancer,” said Bas van der Baan, LIXTE’s Chief Executive Officer.

LIXTE is developing its first-in-class lead clinical PP2A inhibitor, LB-100, as a potentiator of cancer immunotherapy. The Company is testing LB-100 in combination with immunotherapies in clinical trials at the Netherlands Cancer Institute (NKI) in Amsterdam and at The University of Texas MD Anderson Cancer Center in Houston.

At NKI, LIXTE is providing LB-100, and F. Hoffmann-La Roche Ltd. (“Roche”) is providing atezolizumab (Tecentriq^®, a PD-L1 inhibitor) through the imCORE Network as part of a new clinical trial in immune therapy for unresponsive (MSI Low) metastatic colon cancer. The imCORE Network is an academic-industry collaboration that aims to accelerate cancer immunotherapy research through institution-sponsored studies

A second trial underway at MD Anderson is testing the combination of LB-100 and GSK’s dostarlimab-gxly for the treatment of ovarian clear cell carcinoma (OCCC).

The new patent award follows the signing of an exclusive patent license agreement earlier this year between LIXTE and the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH). The agreement provides LIXTE with an opportunity to explore and develop novel combination therapies that can potentially transform the landscape of cancer treatment.

About LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.

LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for colon, ovarian, and sarcoma cancers. Additional information about LIXTE can be found at www.lixte.com.

Forward-Looking Statement Disclaimer

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to obtain and maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.

The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.

Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information about LIXTE, Contact: info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533

or

PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962

FAQ

What is the new patent LIXT received for LB-100?

LIXTE (LIXT) received a Notice of Allowance for a patent application titled 'Oxabicycloheptanes for Modulation of Immune Response,' covering the combination of its LB-100 compound with various cancer immunotherapies.

Where is LIXT conducting clinical trials for LB-100?

LIXTE (LIXT) is conducting clinical trials for LB-100 at the Netherlands Cancer Institute in Amsterdam and The University of Texas MD Anderson Cancer Center in Houston.

What types of cancer is LIXT targeting with LB-100 in its clinical trials?

LIXTE (LIXT) is targeting metastatic colon cancer in the trial at the Netherlands Cancer Institute and ovarian clear cell carcinoma (OCCC) in the trial at MD Anderson Cancer Center.

What recent agreement did LIXT sign with NIH components?

LIXTE (LIXT) signed an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), both components of the National Institute of Health (NIH).